bpc 157 human trials 2025 BPC-157: What the Science Says (Zero Trials) FDA advisers back first four

Neuroprotection Emerging Evidence Evidence Rating: Emerging (Interesting animal data, limited scope) Neurological applications show promise but require more research: Dopaminergic system protection Peripheral nerve regeneration Traumatic brain injury Alcohol-related neurological damage The GABAergic system interactions and NO modulation provide mechanistic support, but this area needs more study

Its also slated for an FDA discussion on reclassification, but not until 2027

Author response: We have made this change in the methods

Ipamorelin belongs to a family of pentapeptides often examined for their possible role as selective secretagogues